Holen Sie sich die Stockscreener-App
5.14
1.58%
0.08
Handel nachbörslich:
5.20
0.06
+1.17%
Schlusskurs vom Vortag:
$5.06
Offen:
$5.12
24-Stunden-Volumen:
300.91K
Relative Volume:
0.61
Marktkapitalisierung:
$1.58B
Einnahmen:
$391.87M
Nettoeinkommen (Verlust:
$-441.45M
KGV:
-2.7784
EPS:
-1.85
Netto-Cashflow:
$-301.21M
1W Leistung:
-6.38%
1M Leistung:
-39.67%
6M Leistung:
-49.41%
1J Leistung:
-58.68%
1-Tages-Spanne:
$5.065
$5.32
1-Wochen-Bereich:
$5.05
$5.49
52-Wochen-Spanne:
$4.70
$13.70
Alvotech Stock (ALVO) Company Profile
Vergleichen Sie ALVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.14 | 1.58B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
122.06 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.82 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Why Alvotech (ALVO) Is Down 7.8% After Surprising Full-Year Revenue Guidance Cut - simplywall.st
New Strong Sell Stocks for Nov. 21st - sharewise.com
Alvotech and Advanz announce EC approval for Gobivaz biosimilar - Pharmaceutical Business review -
Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - PR Newswire
Alvotech and Advanz win EC approval for first Simponi biosimilar - The Pharma Letter
Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar - TipRanks
Gobivaz approved across Europe as first Simponi biosimilar - PharmaTimes
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position - simplywall.st
Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar - Seeking Alpha
European Commission approves Alvotech’s biosimilar golimumab - Investing.com India
European Commission approves Alvotech’s biosimilar golimumab By Investing.com - Investing.com Canada
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - The Manila Times
Will Alvotech (Z45) stock outperform foreign stocks2025 Short Interest & Fast Gaining Stock Reports - newser.com
Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobivaz, fyrstu hliðstæðuna við Simponi - GlobeNewswire
Is Alvotech (Z45) stock attractive for growth fundsTrade Entry Report & AI Forecasted Stock Moves - newser.com
Can Alvotech (Z45) stock reach $200 price target2025 Technical Overview & Fast Momentum Entry Tips - newser.com
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent
What MACD signals say about Alvotech2025 Earnings Surprises & Weekly Return Optimization Alerts - newser.com
Using economic indicators to assess Alvotech Equity Warrant potentialJuly 2025 Summary & High Conviction Buy Zone Alerts - newser.com
Is Alvotech (Z45) stock good for long term investingWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Is Alvotech stock a smart buy before Fed meetingPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing - GlobeNewswire
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewswire Inc.
UBS Group Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
Can Alvotech Equity Warrant stock deliver surprise earnings beatWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Will Alvotech Equity Warrant stock maintain growth storyPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
Alvotech (ALVO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How analysts rate Alvotech stock todayWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
What technical patterns form on Alvotech (Z45) stock charts2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Alvotech Equity Warrant stock deliver shareholder valueLayoff News & Smart Investment Allocation Insights - newser.com
Will Alvotech stock benefit from AI adoptionJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Trend analysis for Alvotech this weekWall Street Watch & Expert Verified Stock Movement Alerts - newser.com
UBS Maintains Alvotech (ALVO) Buy Recommendation - Nasdaq
Is Alvotech (Z45) stock a top dividend aristocrat candidateJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Alvotech at Jefferies London: Strategic Growth Amid Challenges By Investing.com - Investing.com Australia
UBS Maintains Buy Rating on ALVO, Lowers Price Target to $10.00 - GuruFocus
Alvotech at Jefferies London: Strategic Growth Amid Challenges - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alvotech (ALVO) And Encourages Shareholders to Reach Out - ACCESS Newswire
UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating - MarketScreener
What hedge fund activity signals for Alvotech Equity Warrant stockOptions Play & Low Drawdown Investment Ideas - newser.com
ATTENTION ALVO Shareholders: Lost Money on Alvotech? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Alvotech (ALVO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals - TipRanks
Alvotech’s Earnings Call: Growth Amid Challenges - MSN
Will Alvotech stock reach all time highs in 2025July 2025 Update & Daily Entry Point Alerts - newser.com
Why Alvotech stock could outperform in 2025Quarterly Growth Report & Verified Trade Idea Suggestions - newser.com
How Alvotech (Z45) stock trades under stagflationM&A Rumor & Safe Entry Zone Identification - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alvotech (ALVO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Alvotech (ICSE:ALVO) Price Target Decreased by 35.59% to 1,409.50 - Nasdaq
Applying chart zones and confluence areas to AlvotechJuly 2025 Review & Consistent Profit Trade Alerts - newser.com
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):